08:48 AM EDT, 04/18/2024 (MT Newswires) -- TG Therapeutics ( TGTX ) said Thursday that it has been awarded a contract potentially worth about $186.8 million for Briumvi to be the preferred anti-CD20 agent listed on the Department of Veterans Affairs' National Formulary to treat patients with relapsing forms of multiple sclerosis.

The one-year contract, which starts June 17, includes four one-year option periods that can be exercised unilaterally by the US Government, according to the company.

Under the contract, Briumvi will be required for new patient starts unless clinically contraindicated and patients taking other anti-CD20 medications may be switched over to Briumvi by their doctor.

Shares of TG Therapeutics ( TGTX ) were up 1.6% in recent premarket activity.